Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SCB-2019 + alum adjuvant
- Development stage
- Unknown
- Lead developer
- Clover Biopharmaceuticals
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
SCB-2019 + alum adjuvant is a **protein subunit COVID-19 vaccine** composed of a recombinant, trimeric pre-fusion SARS-CoV-2 spike protein (SCB-2019) formulated with an **aluminum hydroxide (alum) adjuvant**, and often also includes CpG 1018. The spike protein is stabilized using Trimer-Tag technology to preserve its native prefusion structure, with the adjuvant included to enhance immunogenicity. The vaccine is administered intramuscularly, primarily in a two-dose schedule spaced four weeks apart. It functions by eliciting a strong antibody and cellular immune response against SARS-CoV-2 and its variants, providing protection against COVID-19 infection, severe disease, and hospitalization. It has shown efficacy in Phase II/III trials and received regulatory authorization in China.
- Other names
- S-Trimer + alum adjuvantTrimeric Recombinant protein-based COVID-19 vaccine adjuvanted with alumSCB-2019 (CpG 1018/alum)
02
Targets
ACE2 (Angiotensin-converting enzyme 2)SARS-CoV-2 spike
Beyond the preview
Go deeper on SCB-2019 + alum adjuvant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SCB-2019 + alum adjuvant.